KRAS G12C
Clinical trials for KRAS G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C trials appear
Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control AVAILABLEThis expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…
Matched conditions: KRAS G12C
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 16, 2026 22:07 UTC
-
New combo tackles lung cancer brain tumors without surgery
Disease control Recruiting nowThis study tests whether combining a targeted pill (adagrasib) with precise radiation (SRS) can control brain tumors in people with a specific type of advanced lung cancer (KRAS G12C mutation). About 30 adults with untreated brain metastases will receive both treatments. The main…
Matched conditions: KRAS G12C
Phase: PHASE2 • Sponsor: Ryan Gentzler, MD • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New targeted drug hopes to shrink tough lung tumors
Disease control Recruiting nowThis early-stage study is testing a new drug called BBO-8520 for people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check the drug's safety and see if it can shrink tumors. About 350 adults will take part, and the…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human trials
Disease control Recruiting nowThis study tests a new drug called FMC-376 in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and shrinks tumors. About 403 adults with lung, colorectal, or pancreatic cancer that has spread or cannot …
Matched conditions: KRAS G12C
Phase: PHASE1, PHASE2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control
Last updated Jun 01, 2026 17:55 UTC
-
New hope for rare blood vessel disorders: targeted drugs enter trial
Disease control Recruiting nowThis study tests two targeted drugs for people with vascular malformations (abnormal blood or lymph vessels). Participants with slow-flow malformations and a specific gene mutation receive alpelisib, while those with fast-flow malformations and another mutation receive mirdametin…
Matched conditions: KRAS G12C
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated May 19, 2026 12:00 UTC